Analyzing existing ECGs to reveal treatment-response patterns in heart-drug trials
Routine ECGs are collected in nearly every cardiovascular trial, but much of their information goes unused beyond conventional interpretation. Differences between patients and weak biological signals complicate trial analysis, increasing the time and resources needed to assess treatment effects.
arterioscope turns existing trial ECGs into AI analyses of patient groups, changes over time and treatment-response patterns. Its research-use software helps biopharma teams explore trial results without collecting new data.
What stands out about arterioscope
Science Park Graz reports that the RUO software MVP is ready and the company is working with its first US pilot customers.
The CEO reports securing over EUR 1M in non-dilutive public funding from sources including FFG and SFG.
Won the Styria Innovation Award 2026 for digitalization among micro and small businesses, for arterioscope.AI-ECG.
Graz University of Technology identifies arterioscope as its spinout, commercializing research by Ranftl and Badeli.
Co-founder Sascha Ranftl holds a TU Graz PhD in theoretical and computational physics and researches scientific machine learning.
Science Park Graz includes arterioscope in its portfolio of incubated startups and alumni.
Co-founder Vahid Badeli developed cardiovascular signal-analysis methods during his electrical-engineering doctorate at TU Graz.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.